SRA's number for the day: 312
This article was originally published in SRA
There are 312 potential first-in-class treatments in development for Alzheimer's, according to US research-based pharmaceutical industry association PhRMA.
The Food and Drug Administration, for its part, is taking steps to help industry meet the most difficult challenges of assessing functional impairment. The FDA has suggested that it might be feasible for the agency to approve new medicines through its accelerated approval pathway on the basis of evaluating cognitive outcome alone.
References
1. US FDA mulling new strategies for OK'ing early-stage Alzheimer's meds, Scrip Regulatory Affairs, 27 March 2013